GULL LABS' CHAGAS' TEST RECEIVES FDA CLEARANCE
GULL LABS' CHAGAS' TEST RECEIVES FDA CLEARANCE SALT LAKE CITY, Utah, July 7 /PRNewswire/ -- Gull Laboratories, Inc.
(NASDAQ: GULL), a Salt Lake City-based medical products manufacturer, announced that its diagnostic test kit for Chagas' disease has received clearance to market notification from the Food & Drug Administration (FDA). Chagas' disease is caused by an infection with the protozoan parasite, Trypanosoma cruzi. Like HIV infection and hepatitis, Chagas' disease is often transmitted by blood transfusion and is a major health problem in children and young adults in Latin America. Severe cases frequently result in death by heart failure. Acute cases of Chagas' disease have also been diagnosed recently in the U.S. and Canada.
The Chagas' lgG ELISA test is one of the company's new series of Color-controlled ELISA tests for infectious diseases, in which the test procedure and the interpretation of results have been simplified and standardized compared to conventional ELISA tests. The Chagas' lgG ELISA test features multiple color changes that mark each important step in the procedure. This feature allows for close monitoring of specimen and reagent additions, reducing the likelihood of procedural error and avoiding expensive repeat testing. Founded in 1974, Gull Laboratories, Inc., develops, manufactures and markets high-quality diagnostic test kits for the detection of infectious diseases. The company markets these products for use in hospitals and clinical laboratories around the world. In addition, Gull manufactures natural medicines and performs health product packaging for the natural health products market. -0- 7/7/92 /CONTACT: Peter Van Duser of Gull Laboratories, 801-263-3524; or John Metzger of Metzger Associates, 303-786-7000, for Gull Laboratories/ (GULL) CO: Gull Laboratories, Inc. ST: Utah IN: MTC SU:
AW-JB -- DV002 -- 6922 07/07/92 10:31 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 7, 1992|
|Previous Article:||DIRECTORS AND OFFICERS OF NONPROFITS SHOW GREATER CONCERN FOR LIABILITY INSURANCE; EMPLOYEES FILING MOST COMPLAINTS, WYATT STUDY FINDS|
|Next Article:||CHEMFIX TECHNOLOGIES POSTS $530,000 THIRD QUARTER PROFIT|